Journey Medical Joins Russell 2000 and 3000 Indices

An announcement from Journey Medical Corp ( (DERM) ) is now available.

On June 24, 2025, Journey Medical Corporation announced its inclusion in the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025. This inclusion is expected to increase the company’s visibility with investors and institutions, potentially impacting its market positioning positively. The company has also launched Emrosi™, an FDA-approved treatment for rosacea, which is off to a strong start, indicating a potentially transformational year for Journey Medical.

The most recent analyst rating on (DERM) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Journey Medical Corp stock, see the DERM Stock Forecast page.

Spark’s Take on DERM Stock

According to Spark, TipRanks’ AI Analyst, DERM is a Neutral.

The overall stock score is heavily influenced by the company’s financial challenges, including declining revenues and negative cash flow. However, the recent successful launch of Emrosi and improved strategic focus provide a positive outlook. The technical analysis and valuation suggest caution, as the stock is experiencing mixed momentum signals and lacks profitability.

To see Spark’s full report on DERM stock, click here.

More about Journey Medical Corp

Journey Medical Corporation is a commercial-stage pharmaceutical company based in Scottsdale, Arizona, primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. The company markets eight branded FDA-approved prescription drugs and is known for its efficient sales and marketing model, with a team of industry experts experienced in dermatology.

Average Trading Volume: 102,556

Technical Sentiment Signal: Buy

Current Market Cap: $151.7M

See more data about DERM stock on TipRanks’ Stock Analysis page.